Copaxone helps reduce the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode.
During the course of the study, mice treated with Copaxone were compared with non-treated mice in relapsing-remitting and chronic multiple sclerosis (MS) disease models.
The data demonstrated remyelination, indicative of repair and a reduction of demyelination and axonal loss in mice treated with the drug candidate.
In addition to remyelination and neuronal preservation, the central nervous system of mice treated with Copaxone had smaller lesions, increased axonal density and a higher prevalence of normal appearing axons, the research concluded.